Business
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. .
About this update from Fate Therapeutics, Inc.
[{"type":"text","content":"BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. .","length":513,"tagName":"p"},{"type":"image","alt":"OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company","displaySize":"","headline":null,"caption":"OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":399,"url":"https://media.zenfs.com/en/prnewswire.com/c3c8935ff33b4a9f0e81fb8e031a1e98"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3L3HMa_9cthWL1gWd3KeNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c3c8935ff33b4a9f0e81fb8e031a1e98","width":400,"height":399}},"href":"https://mma.prnewswire.com/media/2731198/image.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Niethammer is an internationally recognized oncology expert with over two decades of experience in cancer immunotherapy, clinical development, and translational medicine. He previously held leadership roles at global biopharmaceutical companies including Fate Therapeutics, NantKwest (now Immunity Bio), Pfizer, and more recently Aardvark Therapeutics, and has played a pivotal role in the development of novel immuno-oncology platforms, including VXM01.","length":458,"tagName":"p"},{"type":"text","content":"Vaximm was co-founded by Dr. Niethammer to advance and commercialize therapeutic candidates based on his original publications on the concept of oral T-cell vaccination while at the Scripps Research Institute (Nature, 2002). Under his leadership, Vaximm successfully advanced lead candidate, VXM01, into first-in-human clinical studies for both pancreatic cancer and glioblastoma.","length":380,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Dr. Niethammer back to Vaximm as CMO leading Vaximm...